Literature DB >> 24518605

Expression of MACC1 and MET in inflammatory bowel disease-associated colonic neoplasia.

Noam Harpaz1, Sofia Taboada, Huaibin Mabel Ko, Jiangzhou Yu, Qi Yang, Haodong Xu, Wenqing Cao.   

Abstract

BACKGROUND: Metastasis-associated in colon cancer-1 (MACC1), a newly identified regulator of HGF-MET signaling, may participate into the key steps of sporadic colorectal adenocarcinoma development. Given there are many pathogenetic distinctions between colitis-associated colorectal cancer (CAC) and sporadic colorectal adenocarcinomas, the potential roles of MACC1 in CAC carcinogenesis remain unknown. For the first time, we evaluated the expressions of MACC1 and MET in IBD-associated colitis, dysplasia, and adenocarcinoma.
METHODS: Expression was investigated by immunohistochemistry in tissue microarrays consisting of 13 normal colon, 11 active colitis, 9 dysplasia, 51 conventional CAC, 5 mucinous adenocarcinoma, and 1 signet ring cell adenocarcinoma specimens. The expression level of MACC1 or MET was evaluated with H-score system.
RESULTS: MACC1 expression was significantly higher in IBD-associated dysplasia than that in corresponding inflammatory or normal colonic tissue, and its level was further elevated from dysplasia to conventional CAC. Higher MACC1 expression was seen in a patient with CAC who had multifocal dysplasia or synchronous carcinoma. MACC1 overexpression (H-score >100) was seen in 67% of conventional CAC but in 0% of dysplasia and 0% of inflammation or normal colon. There was no difference of MACC1 expression found among well, moderately and poorly differentiated CAC. MET expressions in inflammation, dysplasia, and conventional CAC were statistically similar. No parallel expression of MACC1 and MET was detected in this study. MACC1 and MET expression was not increased in mucinous or signet ring cell carcinoma, 2 distinct variants of CAC.
CONCLUSIONS: Stepwise increase of MACC1 expression from IBD-associated colitis to dysplasia to adenocarcinoma suggests that MACC1 is strongly associated with conventional CAC tumorigenesis in a manner independent of MET. MACC1 may serve as a potential marker for early diagnosis of conventional CAC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24518605     DOI: 10.1097/01.MIB.0000442679.39804.48

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  8 in total

1.  c-MET immunohistochemical expression in sporadic and inflammatory bowel disease associated lesions.

Authors:  Grant Halliday; Ross J Porter; Catherine J Black; Mark J Arends; Shahida Din
Journal:  World J Gastroenterol       Date:  2022-04-07       Impact factor: 5.374

Review 2.  Prognostic Value of MACC1 in Digestive System Neoplasms: A Systematic Review and Meta-Analysis.

Authors:  Zhenzhen Wu; Rui Zhou; Yuqi Su; Li Sun; Yulin Liao; Wangjun Liao
Journal:  Biomed Res Int       Date:  2015-05-19       Impact factor: 3.411

Review 3.  Early detection of ulcerative colitis-associated colorectal cancer.

Authors:  Yu Zhen; Chengxin Luo; Hu Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-05-14

4.  Correlation of MACC1/c-Myc Expression in Endometrial Carcinoma with Clinical/Pathological Features or Prognosis.

Authors:  Qinghua Zhang; Ping Xu; Yanxia Lu; Hongtao Dou
Journal:  Med Sci Monit       Date:  2018-07-09

5.  Metastasis-associated in colon cancer 1: A promising biomarker for the metastasis and prognosis of colorectal cancer.

Authors:  He Li; Yi-Xin Chen; Jia-Gen Wen; Hong-Hao Zhou
Journal:  Oncol Lett       Date:  2017-07-26       Impact factor: 2.967

6.  Elevated MACC1 Expression in Colorectal Cancer Is Driven by Chromosomal Instability and Is Associated with Molecular Subtype and Worse Patient Survival.

Authors:  Vincent Vuaroqueaux; Alexandra Musch; Dennis Kobelt; Thomas Risch; Pia Herrmann; Susen Burock; Anne-Lise Peille; Marie-Laure Yaspo; Heinz-Herbert Fiebig; Ulrike Stein
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

7.  Statin and rottlerin small-molecule inhibitors restrict colon cancer progression and metastasis via MACC1.

Authors:  Manisha Juneja; Dennis Kobelt; Wolfgang Walther; Cynthia Voss; Janice Smith; Edgar Specker; Martin Neuenschwander; Björn-Oliver Gohlke; Mathias Dahlmann; Silke Radetzki; Robert Preissner; Jens Peter von Kries; Peter Michael Schlag; Ulrike Stein
Journal:  PLoS Biol       Date:  2017-06-01       Impact factor: 8.029

8.  Immunohistochemical expression of insulin-like growth factor-1Ec in primary endometrial carcinoma: Association with PTEN, p53 and survivin expression.

Authors:  Aggelis Stavropoulos; Michail Varras; Anastassios Philippou; Thivi Vasilakaki; Viktoria-Konstantina Varra; Fani-Niki Varra; Aikaterini Tsavari; Andreas C Lazaris; Michael Koutsilieris
Journal:  Oncol Lett       Date:  2020-10-29       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.